Tag: AstraZeneca

AstraZeneca is a British–Swedish multinational pharmaceutical and biopharmaceutical company. In 2013 it moved its headquarters to Cambridge, England, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015 it was the eighth largest drug company in the world based on sales revenue.

Russia is one of the key markets for the company “AstraZeneca”. In October 2015 in the Kaluga region took place the grand opening of the company’s plant in Russia. Total investment in the creation of the company was $224 million. In addition, “AstraZeneca” is one of the largest companies that invest in scientific and research activities. In Russia, company conducts clinical research, which today includes more than six thousand patients. Seven and a half thousand patients participating in company studies, clinical practice. In 2016 company expanded scientific cooperation with Russian Society of Clinical Oncology and continued partnership with “Skolkovo” biomedcluster.

US Court to Hear Aurobindo Pharma over Patent Infringement Allegations

court
Pharma major AstraZeneca has filed a petition in a US court, alleging that Aurobindo Pharma is attempting to come out with the generic version of its patented drug Daliresp (Roflumilast Tablet 500 mcg...

New Data Demonstrated the Effectiveness of AstraZeneca’s Symbicort Turbuhaler

astrazeneca
New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol) as a potential anti-inflammat...

AstraZeneca Announced Positive Results from the Phase III Trial of Calquence

AstraZeneca today announced positive results from the Phase III ASCEND trial of Calquence (acalabrutinib) in previously-treated patients with chronic lymphocytic leukaemia (CLL). Results showed a stat...

AstraZeneca Qternmet XR Approved in the USA

The US Food and Drug Administration (FDA) has approved Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) extended release tablets as an oral adjunct treatment to diet and exercise t...

AstraZeneca and Transgene Agreed to Develop Viral Immunotherapies

astrazeneca
British drugmaker AstraZeneca Plc and French biopharmaceutical firm Transgene SA entered into an agreement on Thursday to co-develop five cancer-killing viral immunotherapies. Viral immunotherapy r...

AstraZeneca Announce Cooperation to Accelerate Drug Discovery

astrazeneca
AstraZeneca and BenevolentAI began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treatments for chronic kidney disea...

AstraZeneca to Pay Daiichi-Sankyo $6.9 billion for Shared Rights to a New Cancer Drug

AstraZeneca Strikes $6.9 Billion Cancer Deal With Japanese Drugmaker. Deal for part of the rights to Daiichi Sankyo’s antibody drug is part of Astra’s heavy investment in cancer research. In a move...

CPI Partenrs with GSK and AZ to Create New Site

GSK, AstraZeneca, and GEA join resources to create a site in the UK for developing small-scale oral solid dosage APIs. CPI is collaborating with partners GSK and AstraZeneca to establish a bespoke,...

ThiIrd Lynparza Indication in EU

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced the European Commission has approved Lynparza (olaparib) as a monotherapy ...

BTD for AstraZeneca and Merck Med

AstraZeneca and MSD, Inc., Kenilworth, NJ, US announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the MEK 1/2 inhibitor and potential new me...

Promicing Lung Cancer Treatment Will Be Available on NHS

NICE has today published draft final guidance recommending durvalumab (Imfinzi, AstraZeneca). It will be made available on the NHS in England immediately for people with locally advanced unresectab...

Forxiga Got Another Approval

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T1D). Elisabeth Björk, Senio...

First Approved AZ’s Med for Type-1 Diabetes

Forxiga is the first oral medicine approved in Europe as an adjunct to insulin for adults with type-1 diabetes and the first AstraZeneca medicine ever approved for type-1 diabetes. The European Com...

AZ’s Diabetes Drug Reduces Heart Failure Risk

Farxiga reduced hospitalisation for heart failure regardless of ejection fraction status. Positive results from a pre-specified sub-analysis of the Phase III DECLARE-TIMI 58 trial showed that Farxi...

AstraZeneca New Med for Rare Disease Got ODD

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for saracatinib, a potential new medicine for the treatment of idiopathic pulmonary fibrosis (IPF), a type of lung d...

Seres and AstraZeneca in Immuno-Oncology Collaboration

Seres Therapeutics, Inc. announced a three-year research collaboration with AstraZeneca. The collaboration will focus on advancing mechanistic understanding of the microbiome in augmenting the efficac...